BSE Live
Dec 29, 16:01Prev. Close
1205.95
Open Price
1223.10
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 29, 15:51Prev. Close
1206.20
Open Price
1206.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1200.10 (590)
| Balance Sheet of Aurobindo Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.52 | |
| Total Share Capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.52 | |
| Reserves and Surplus | 16,751.79 | 13,832.13 | 11,621.83 | 9,313.32 | 7,228.78 | |
| Total Reserves and Surplus | 16,751.79 | 13,832.13 | 11,621.83 | 9,313.32 | 7,228.78 | |
| Total Shareholders Funds | 16,810.38 | 13,890.78 | 11,680.42 | 9,371.91 | 7,287.30 | |
| Minority Interest | 0.14 | 1.59 | 1.82 | 2.08 | 2.55 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 179.95 | 451.20 | 181.40 | 742.81 | |
| Deferred Tax Liabilities [Net] | 302.48 | 281.31 | 235.28 | 49.30 | 23.96 | |
| Other Long Term Liabilities | 351.89 | 33.62 | 10.57 | 0.00 | 0.00 | |
| Long Term Provisions | 74.71 | 46.54 | 55.86 | 39.13 | 23.36 | |
| Total Non-Current Liabilities | 729.08 | 541.42 | 752.91 | 269.83 | 790.13 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 5,422.30 | 6,573.21 | 4,031.34 | 2,902.72 | 3,672.68 | |
| Trade Payables | 2,545.01 | 2,552.18 | 2,372.90 | 2,154.70 | 2,457.03 | |
| Other Current Liabilities | 3,002.80 | 2,576.78 | 2,064.37 | 1,313.28 | 1,659.59 | |
| Short Term Provisions | 416.64 | 318.40 | 197.28 | 234.90 | 50.92 | |
| Total Current Liabilities | 11,386.75 | 12,020.57 | 8,665.89 | 6,605.60 | 7,840.22 | |
| Total Capital And Liabilities | 28,926.35 | 26,454.36 | 21,101.04 | 16,249.42 | 15,920.20 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 6,494.81 | 5,693.65 | 4,736.56 | 4,083.05 | 3,380.39 | |
| Intangible Assets | 1,985.72 | 1,948.69 | 967.57 | 344.43 | 393.00 | |
| Capital Work-In-Progress | 1,621.82 | 1,341.94 | 1,399.54 | 1,237.36 | 835.90 | |
| Fixed Assets | 10,466.47 | 9,310.80 | 7,287.17 | 5,885.56 | 4,621.53 | |
| Non-Current Investments | 554.69 | 360.20 | 311.52 | 245.85 | 122.94 | |
| Deferred Tax Assets [Net] | 163.20 | 183.29 | 158.80 | 167.76 | 206.28 | |
| Long Term Loans And Advances | 5.84 | 6.46 | 5.44 | 5.70 | 5.45 | |
| Other Non-Current Assets | 407.71 | 428.80 | 343.40 | 332.07 | 263.35 | |
| Total Non-Current Assets | 12,513.85 | 11,122.06 | 8,922.88 | 7,043.24 | 5,625.85 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Inventories | 7,699.87 | 7,245.60 | 5,858.41 | 4,330.54 | 4,056.14 | |
| Trade Receivables | 4,315.15 | 3,413.78 | 3,080.20 | 2,765.33 | 4,606.68 | |
| Cash And Cash Equivalents | 2,842.15 | 1,957.18 | 1,262.25 | 513.48 | 800.26 | |
| Short Term Loans And Advances | 13.68 | 10.26 | 8.66 | 10.89 | 10.31 | |
| OtherCurrentAssets | 1,541.63 | 2,705.46 | 1,968.62 | 1,585.92 | 820.94 | |
| Total Current Assets | 16,412.50 | 15,332.30 | 12,178.16 | 9,206.18 | 10,294.35 | |
| Total Assets | 28,926.35 | 26,454.36 | 21,101.04 | 16,249.42 | 15,920.20 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 659.39 | 688.84 | 716.95 | 0.00 | 0.00 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 46.55 | 46.55 | 46.55 | 46.55 | 46.55 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 145.08 | 112.64 | 80.73 | 245.85 | 0.14 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
19.12.2025
15.12.2025
04.12.2025
23.11.2025
Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL